ProMIS Neurosciences Inc. Common Shares (ON)

ProMIS Neurosciences announced positive Phase 1a trial results showing PMN310, its lead Alzheimer's drug candidate, achieved dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid. The company demonstrated target engagement in healthy volunteers and plans to present six-month blinded interim data from its Phase 1b PRECISE...

ProMIS Neurosciences is implementing a one-for-twenty-five reverse stock split to address Nasdaq listing requirements and potentially increase its stock price, reducing outstanding shares from approximately 53.8 million to 2.15 million.

ProMIS Neurosciences secured $3 million in private financing through a PIPE offering, with an additional $9 million from warrant exercises, totaling approximately $12 million in gross proceeds to advance clinical development of PMN310 and support corporate operations.

The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical tr...

ProMIS Neurosciences announced positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310, an antibody therapeutic targeting toxic misfolded proteins in Alzheimer's disease. The data showed a favorable safety profile, dose-dependent levels of PMN310 in the cerebrospinal fluid, and potential for target engagement i...